Pheej Yig Tshuaj Txhaum Yuav Tsum Kho Mob-Kuj Qhov Ntshav

Leukemia yog ib cov kab mob ntshav uas ua kom cov qe ntshav dawb ntau dhau. Muaj ob hom mob qog mob ntshav ntswg uas maj mam dhau los ntau xyoo thiab mob ceev cov ntshav muaj leukemia uas hloov zuj zus mus. AML cuam tshuam rau ntau dua ntawm 20, 000 tus neeg hauv Tebchaws Meskas txhua xyoo, thiab kev muaj kev tuag yog qhov tshwj xeeb tshaj yog rau cov neeg laus.

Ib qho tshuaj feem ntau los kho AML yog cytarabine (ara-C), ib qho tshuaj cytotoxic uas cuam tshuam nrog kev rov ua DNA. Txawm li cas los xij, ntau tus neeg mob tsis teb rau txoj kev kho vim tias lawv cov qog ntshav tawm hais tias muaj ntau theem ntawm enzyme SAMHD {{{1}}, uas txhawm rau cov tshuaj metabolite ntawm cytarabine, ara-CTP. Cov neeg mob no muaj feem ua rau muaj sia nyob ntau dua li cov neeg mob uas tsis muaj ntshav qab zib tsawg SAMHD {{1}}. Yog li, ib qho kev cog lus zoo los txhim kho txoj kev kho mob ntawm AML yog rau inhibit qhov kev cuam tshuam ntawm no enzyme ntawm cytarabine.

Hauv qhov kev tshawb nrhiav no, cov kws tshawb nrhiav tau sim ntau dua li ntawm 33, 000 ntau yam sib txawv ntawm SAMHD1 & # 39; muaj peev xwm txhawm rau txo ara-CTP hauv cov ntshav qog ntshav kho nrog cytarabine. Cov kev sim coj ua rau kev txheeb xyuas peb yam sib txawv, yog li hu ua ribonucleotide reductase inhibitors (RNRi), tias txhua yam txo SAMHD1 & # 39; s muaj peev xwm deactivate ara-CTP: hydroxyurea, gemcitabine thiab triapine.

0010010 quot; Ntxiv rau ib qho ntawm peb yam no cuam tshuam rau kev cuam tshuam ntawm kev kho mob cytarabine hauv kev kuaj mob ntawm tes nrog cov qib siab ntawm SAMHD 1, 0010010 quot; hais tias Nikolas Herold, tus kws tshawb fawb nyob rau hauv Department of Women 0010010 # 39; s thiab Cov Menyuam 0010010 ; # 39; 0010010 quot; Qhov no muaj tseeb rau cov qauv AML ntawm ob tus neeg laus thiab menyuam yaus. Hauv AML-nas, peb kuj pom tias qhov nruab nrab muaj sia nyob ntev dua thaum cytarabine sib xyaw nrog RNR-inhibitor. 0010010 quot;

Hydroxyurea yog ib qho tshuaj pheej yig uas siv los kho cov ntshav xws li AML. Txawm li cas los xij, nws tsis tau siv systematically siv nrog cytarabine. Gemcitabine yog cov tshuaj muaj zog uas tau siv los kho ntau hom mob qog nqaij hlav, tab sis nws tuaj yeem ua tau lom yog tias muab ntau zaus. Triapine yog ib hom tshuaj uas tam sim no tseem tshawb fawb txog kev kho mob cancer. Hauv cov kev tshawb fawb tsiaj, kev sib xyaw ua ke tsis tau ua rau pom muaj kev phiv ntau dua li cov uas twb tau tsim hauv cytarabine-kev kho mob.

Cov pab pawg tshawb nrhiav tam sim no npaj mus tom ntej nrog qhov kev tshawb fawb soj ntsuam uas yuav soj ntsuam cov txiaj ntsig ntawm kev sib txuas ntawm cov qauv tshuaj AML-kev kho nrog hydroxyurea hauv cov neeg mob uas nyuam qhuav soj ntsuam. Txoj kev kawm no yuav muaj kev koom tes nrog Swedish AML-pawg thiab yuav pib nrhiav cov neeg mob hauv ob peb lub lis piam.

0010010 quot; Hydroxyurea yog ib qho tshuaj pom zoo uas twb siv los kho AML, yog li peb xav tias nws muaj peev xwm loj, 0010010 quot; hais Nikolas Herold. 0010010 quot; Yog tias peb cov kev tshawb pom tau tshawb pom tseeb hauv kev sim tshuaj, kev kho mob ntawm AML kuj tuaj yeem txhim kho tau tseem ceeb hauv cov tebchaws tseem muaj kev txwv vim tias hydroxyurea tsis muaj patent thiab tsis 0010010 # {{5 }}; t nqi ntau dua ibuprofen. 0010010 quot;

Cov kws tshawb nrhiav kuj tseem muaj peev xwm qhia tau li cas RNR-inhibitors cuam tshuam SAMHD1-qib mechanistically. Cov tshuaj no hloov cov tshuaj sib xyaw ua ke ntawm deoxynucleoside triphosphates (dNTP), uas yog tsim cov tsev sib xyaw rau cov lwg me me. Txij li SAMHD 1 xav tau dNTPs los ua kom nws qhov kev ua si enzymatic, qhov no zoo tshem tawm nws lub peev xwm los rhuav tshem ara-CTP.

Tau txais los ntawm: https://www.sciencedaily.com/releases/2020/01/200117080826.htm